# Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.

> **NCT00388440** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 150 (actual)

## Conditions studied

- Rubella
- Mumps
- Measles

## Interventions

- **BIOLOGICAL:** MMR vaccine (Priorix)

## Key facts

- **NCT ID:** NCT00388440
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** 2001-04
- **Final completion:** 2001-04
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2016-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00388440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00388440, "Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00388440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*